Clene

Clene Net Tangible Assets

The Net Tangible Assets of Clene (CLNN) as of Nov 15, 2026 is -17.59 M USD. In the previous year, Net Tangible Assets was -8.86 M USD — a change of 98.62% (lower).

Net Tangible Assets

-17.59 MUSD

YoY

98.62%

Last updated:

Net Tangible Assets of Clene is 2025 -17.59 M USD. Net Tangible Assets of Clene was 2024 -8.86 M USD. It decreases by 98.62% lower compared to the previous year.

The Clene Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2018
5.00 M USD
Jan 1, 2019
4.89 M USD
Jan 1, 2020
341,000.00 USD
Jan 1, 2021
12.60 M USD
Jan 1, 2022
3.24 M USD
Jan 1, 2023
13.39 M USD
Jan 1, 2024
-8.86 M USD
Jan 1, 2025
-17.59 M USD
The Clene Net Tangible Assets history
YEARNet Tangible AssetsYoY
-17.59 MUSD+98.62%
-8.86 MUSD-166.15%
13.39 MUSD+313.65%
3.24 MUSD-74.30%
12.60 MUSD+3,594.13%
341,000.00USD-93.02%
4.89 MUSD-2.26%
5.00 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clene Stock analysis

What does Clene do? Clene Inc develops therapeutic products for neurodegenerative diseases, focusing on targeting energetic failure as a root cause. Its primary product CNM-Au8 is an oral suspension of gold nanocrystals designed to restore neuronal health by enhancing energy production and utilization. The company also develops CNM-ZnAg, a spectrum antiviral and antibacterial agent containing zinc and silver ions for infectious disease treatment and immune support, and CNM-AgZn17, a gel polymer suspension of zinc and silver for wound healing and infectious disease management. These products are intended for clinical development and eventual commercialization in the pharmaceutical market. Clene's target customers are patients suffering from neurodegenerative diseases and infectious conditions requiring antiviral, antibacterial, or wound healing solutions. The company's products aim to address unmet medical needs in these therapeutic areas by leveraging innovative nanocrystal and ion-based technologies. The firm operates within the biopharmaceutical sector, developing treatments that focus on cellular energy processes to provide neuroprotection and remyelination. The company generates revenue through the development and potential future commercialization of its drug candidates. CNM-Au8 targets neurodegenerative diseases by addressing energetic failure, while CNM-ZnAg and CNM-AgZn17 focus on infectious disease treatment and wound healing applications. These products are in clinical development stages, with the company seeking to advance them toward regulatory approval and market entry. Clene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clene stock

Net Tangible Assets of Clene is -17.59 M USD in 2025.

Net Tangible Assets of Clene changed from -8.86 M USD to -17.59 M USD, representing a 98.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets Clene since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Clene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Clene

All Key Metrics — Clene